GlaxoSmithKline PLC Return On Asset Over Time

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets. Please check GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation.

Search Competitors Fundamentals Over Time Against Return On Asset

 
Refresh
GlaxoSmithKline PLC Return on Invested Capital is decreasing as compared to previous years. The last year's value of Return on Invested Capital was reported at 0.17. The current Return on Sales is estimated to increase to 0.20, while Net Current Assets as percentage of Total Assets are estimated to decrease to (5.87) .

Specify up to 10 symbols:


Cross Equities Return on Average Assets Analysis

Compare GlaxoSmithKline PLC and related stocks such as Astrazeneca PLC, Bristol Myers Squibb, Johnson Johnson, Eli Lilly And, Merck Inc, Novartis AG, Gilead Sciences, Grifols S A, GW Pharmaceuticals Plc Return On Asset Over Time
Select Fundamental

20102011201220132014201520162017201820192020
0.1480.1870.120.0480.0210.0510.0540.0450.0330.020.0205
0.3490.1160.0580.0690.060.0490.1350.030.1460.050.0726
0.1340.1250.1090.130.0670.1790.0160.0270.0630.0670.0718
0.0870.0870.1190.1190.1190.1190.1190.0090.0980.0090.0092
0.160.1330.1230.1390.0680.0670.074(0.005)0.0740.2160.2347
0.2010.0590.0580.0410.1170.0430.040.0260.0730.1180.1253
0.0970.0740.0770.0730.0810.1380.0510.0590.0910.0890.0821
0.3050.2020.1250.1370.3940.4030.2560.0730.0840.0870.1353
0.0650.0130.0460.060.0660.0590.0550.0630.0510.0450.0539
(0.632)(0.632)(0.632)(0.632)(0.632)(0.632)(0.632)(0.632)(0.011)(0.0126)(0.0136)

GlaxoSmithKline PLC and related stocks such as Astrazeneca PLC, Bristol Myers Squibb, Johnson Johnson, Eli Lilly And, Merck Inc, Novartis AG, Gilead Sciences, Grifols S A, GW Pharmaceuticals Plc Return on Average Assets description

Return on assets measures how profitable a company is Net Income Common Stock relative to its total assets [AssetsAvg].

My Equities

My Current Equities and Potential Positions

GSK - USA Stock
GlaxoSmithKline PLC
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>GP</div>
GlaxoSmithKline PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
RegionEurope
ExchangeBATS Exchange
$41.22
Please check GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation. Please also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page